Klin Farmakol Farm. 2008;22(1):11-14

Risk perceptions in the antiaggregation preventive therapy

Milan Kriška^1,2, Ján Rajec³, Ján Kriška⁴, Ewald Ambrózy³, Ján Gajdošík⁵, Andrej Dukát³

¹ Farmakologický ústav Lekárskej fakulty UK, Bratislava

² Nemocnica s poliklinikou Považská Bystrica

³ II. interná klinika LF UK, FN Bratislava

⁴ Blue Ridge Cardiology. MtAiry, NC, USA

⁵ Všeobecný lekár, Nové Zámky

There is high level of evidence available to prove the efficacy of preventive antithrombotic therapy in the reduction of acute vascular events. On the other hand, there is considerable risk associated with this therapy. Bleeding and other adverse drug reactions often limit the usage of the basic antiplatelet drug, that is aspirin. Clopidogrel has proved better tolerance as well as effectivity in this setting. The inadequate drug risk perception may negatively influence the prescriptive decisions of doctors and patients´ adherence to the treatment. The authors of the review article aimed to show the limits of the chosen drugs.

Keywords: Key words: risk perceptions, safety of drugs, adherence to the treatment, aspirin.

Published: April 1, 2008  Show citation